Kevin David Costa
Corporate Officer/Principal chez Icahn School of Medicine at Mount Sinai
Profil
Kevin David Costa was the founder and had founded Novoheart Holdings, Inc. in 1964 where he held the title of Chief Scientific Officer.
Currently, he is the Director-Cardiovascular Cell & Tissue Engineering at Icahn School of Medicine at Mount Sinai since 2009.
Previously, he worked as an Associate Professor at The Trustees of Columbia University in The City of New York.
Dr. Costa received his undergraduate and graduate degrees from Boston University and his doctorate from the University of California San Diego.
Postes actifs de Kevin David Costa
| Sociétés | Poste | Début |
|---|---|---|
| Icahn School of Medicine at Mount Sinai | Corporate Officer/Principal | 01/01/2009 |
Anciens postes connus de Kevin David Costa
| Sociétés | Poste | Fin |
|---|---|---|
| The Trustees of Columbia University in The City of New York | Corporate Officer/Principal | - |
| NOVOHEART HOLDINGS INC. | Fondateur | - |
Formation de Kevin David Costa
| Boston University | Graduate Degree |
| University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Novoheart Holdings, Inc.
 Novoheart Holdings, Inc. BiotechnologyHealth Technology Novoheart Holdings, Inc. is a global stem cell biotechnology company. It engages in engineering prototypes of bio-artificial human heart tissues and chambers for drug discovery, cardio toxicity screening, diseases modeling and therapeutic applications. The firm products include Human Ventricular Cardiomyocytes (hvCM), Cardiac Anisotropic Sheet (hvCAS), Cardiac Anisotropic Patch (hvCAP), Cardiac Tissue Strip (hvCTS), and novoHeart. The company was founded by Michelle Khine, Kevin Costa and Ronald Li on April 28, 1964 and is headquartered in Vancouver, Canada. | Health Technology |